BiotechTube

S-217622 + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2 Infection

Conditions

SARS-CoV-2 Infection

Trial Timeline

Jun 9, 2023 → Sep 18, 2024

NCT ID
NCT05897541

About S-217622 + Placebo

S-217622 + Placebo is a phase 3 stage product being developed by Shionogi for SARS-CoV-2 Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05897541. Target conditions include SARS-CoV-2 Infection.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT05897541Phase 3Completed
NCT05305547Phase 3Completed

Competing Products

20 competing products in SARS-CoV-2 Infection

See all competitors
ProductCompanyStageHype Score
CT-P59CelltrionPhase 1
33
CT-P63 + PlaceboCelltrionPhase 1
33
CT-P59 + CT-P59 + Placebo + CT-P59 + PlaceboCelltrionPhase 2/3
65
CT-P59 + PlaceboCelltrionPhase 1
33
S-268019-b + PlaceboShionogiPhase 3
77
S-217622 + PlaceboShionogiPhase 3
77
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
Nitric OxideGlenmark PharmaceuticalsPhase 3
77
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
52
EvusheldAstraZenecaPre-clinical
23
Biological: AZD3152 + Biological: PlaceboAstraZenecaPhase 2
52
AZD5156 (Parent study Sentinel Safety Cohort) + Placebo (Parent study Sentinel Safety Cohort) + EVUSHELD™ (Parent study Main Cohort) + AZD3152 (Parent study Main Cohort) + Placebo (Parent study Main Cohort) + AZD3152 (Sub-study) + AZD7442 - EVUSHELD™ (Sub-study) + AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152AstraZenecaPhase 2/3
65
EVUSHELDAstraZenecaPre-clinical
23
AZD1222AstraZenecaApproved
85
AZD3152 (Cohort 1) + Placebo (Cohort 1) + AZD3152 (Cohort 2) + Placebo (Cohort 2) + AZD3152 (Cohort 3) + Placebo (Cohort 3)AstraZenecaPhase 1
33
EVUSHELDAstraZenecaPre-clinical
23
AZD7442AstraZenecaPhase 1
33
EVUSHELDAstraZenecaPre-clinical
23
Molnupiravir 200 mg + Molnupiravir 400 mg + Molnupiravir 800 mg + Placebo (PBO)MerckPhase 2
52
Tocilizumab (TCZ) + PlaceboRochePhase 2
52

Other Products from Shionogi

Naldemedine + PlaceboApproved
85
Rosuvastatin + HMG CoA inhibitorApproved
85
StatinApproved
85
CefiderocolApproved
85
Duloxetine + Pregabalin + PlaceboApproved
85